On the road to eliminating long‐lived plasma cells—“are we there yet?”

Markmann, Caroline; Bhoj, Vijay

doi:10.1111/imr.13015

Cited by 14 publications

(13 citation statements)

References 172 publications

(211 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further, this raises an intriguing possibility that targeting CD102 or other cellular adhesion markers in humans could provide therapeutic efficacy for treating human disease driven by abnormal PC responses. Multiple myeloma, a PC cancer, and lupus, an autoimmune disorder driven by self-reactive antibody, are two diseases that could benefit from new therapeutic modalities 63 . Multiple myeloma is typically treated with chemotherapy, radiation, or stem cell transplantation 64 .…”

Section: Discussionmentioning

confidence: 99%

Single cell multi-omic reference atlases of non-human primate immune tissues reveals CD102 as a biomarker for long-lived plasma cells

Staupe

Lodge²,

Thambi

et al. 2022

Commun Biol

View full text Add to dashboard Cite

In response to infection or immunization, antibodies are produced that provide protection against re-exposure with the same pathogen. These antibodies can persist at high titers for decades and are maintained by bone marrow-resident long-lived plasma cells (LLPC). However, the durability of antibody responses to immunization varies amongst vaccines. It is unknown what factors contribute to the differential longevity of serum antibody responses and whether heterogeneity in LLPC contributes to this phenomenon. While LLPC differentiation has been studied extensively in mice, little is known about this population in humans or non-human primates (NHP). Here, we use multi-omic single-cell profiling to identify and characterize the LLPC compartment in NHP. We identify LLPC biomarkers including the marker CD102 and show that CD102 in combination with CD31 identifies LLPC in NHP bone marrow. Additionally, we find that CD102 is expressed by LLPC in mouse and humans. These results further our understanding of the LLPC compartment in NHP, identify biomarkers of LLPC, and provide tissue-specific single cell references for future studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Single cell multi-omic reference atlases of non-human primate immune tissues reveals CD102 as a biomarker for long-lived plasma cells

Staupe

Lodge²,

Thambi

et al. 2022

Commun Biol

View full text Add to dashboard Cite

show abstract

“…Rituximab depletes peripheral B cells (>90%) but has no effect on memory B, plasma, and T cells. 12,13 The rates of CR in small series of adult and pediatric populations were 61% and 40%, respectively. Not surprisingly, the efficacy of rituximab without ITI is modest or even poor.…”

Section: The Role Of Ist Coupled With Itimentioning

confidence: 98%

Immune complications and their management in inherited and acquired bleeding disorders

Arruda

Lillicrap

Herzog

2022

Blood

View full text Add to dashboard Cite

Disorders of coagulation, resulting in serious risks for bleeding, may be caused by autoantibody formation or by mutations in genes encoding coagulation factors. In the latter case, antidrug antibodies (ADAs) may form against the clotting factor protein drugs used in replacement therapy, as is well documented in the treatment of the X-linked disease hemophilia. Such neutralizing antibodies against factors VIII or IX substantially complicate treatment. Autoantibody formation against factor VIII leads to acquired hemophilia. Although rare, antibody formation may occur in the treatment of other clotting factor deficiencies (eg, against von Willebrand factor [VWF]). The main strategies that have emerged to address these immune responses include (1) clinical immune tolerance induction (ITI) protocols; (2) immune suppression therapies (ISTs); and (3) the development of drugs that can improve hemostasis while bypassing the antibodies against coagulation factors altogether (some of these nonfactor therapies/NFTs are antibody-based, but they are distinct from traditional immunotherapy as they do not target the immune system). Choice of immune or alternative therapy and criteria for selection of a specific regimen for inherited and autoimmune bleeding disorders are explained. ITI serves as an important proof of principle that antigen-specific immune tolerance can be achieved in humans through repeated antigen administration, even in the absence of immune suppression. Finally, novel immunotherapy approaches that are still in the preclinical phase, such as cellular (for instance, regulatory T cell [Treg]) immunotherapies, gene therapy, and oral antigen administration, are discussed.

show abstract

“…Although FO B cells also participate in T-cell-independent (TI) IgM responses, they are mainly differentiated with the help of T lymphocytes into long-lived plasma cells and classswitched memory B cells that produce high-affinity IgG antibodies and mediate the classical humoral immune response [30]. Long-lived plasma cells consistently produce highaffinity antibodies, and although they do not express antigen receptors and cannot sense antigens, they continue to release their products as high-affinity antibody factories as the first line of defense against reinfection [42][43][44]. Class-switched memory B cells express specific antigen receptors that trigger a memory response when the antigen is encountered again.…”

Section: The Significance Of B Cells In Sepsismentioning

confidence: 99%

Insights into the Roles of B Cells in Patients with Sepsis

Dong

Qin

et al. 2023

Journal of Immunology Research

View full text Add to dashboard Cite

Sepsis is a life-threatening yet common disease, still posing high mortality worldwide. Sepsis-related deaths primarily occur during immunosuppression; the disease can hamper the numbers and function of B cells, which mediate innate and adaptive immune responses to maintain immune homeostasis. Dysfunction of B cells, along with aggravated immunosuppression, are closely related to poor prognosis. However, B cells in patients with sepsis have garnered little attention. This article focuses on the significance of B-cell subsets, including regulatory B cells, in sepsis and how the counts and function of circulating B cells are affected in patients with sepsis. Finally, potential B-cell-related immunotherapies for sepsis are explored.

show abstract

On the road to eliminating long‐lived plasma cells—“are we there yet?”

Cited by 14 publications

References 172 publications

Single cell multi-omic reference atlases of non-human primate immune tissues reveals CD102 as a biomarker for long-lived plasma cells

Single cell multi-omic reference atlases of non-human primate immune tissues reveals CD102 as a biomarker for long-lived plasma cells

Immune complications and their management in inherited and acquired bleeding disorders

Insights into the Roles of B Cells in Patients with Sepsis

Contact Info

Product

Resources

About